Fintel reports that on April 10, 2025, Scotiabank downgraded their outlook for Tempest Therapeutics (NasdaqCM:TPST) from ...

Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cancer ...

According to Tempest, its options include a partnership or licensing deal, as well as a merger or an acquisition.

California-based clinical-stage biotech Tempest Therapeutics (Nasdaq: TPST) has announced that the company plans to explore a ...

Fintel reports that on April 10, 2025, HC Wainwright & Co. downgraded their outlook for Tempest Therapeutics (NasdaqCM:TPST) ...

Tempest Therapeutics is eyeing a strategic partner to continue amezalpat’s development amid ‘unavailable capital markets'.

Unable to secure additional financing amid a stormy market, Tempest Therapeutics has put a call out for partners as it seeks ...

Tempest Therapeutics is mulling its business options, including potential exit pathways, after an inability to raise cash to bankroll its lead cancer asset through a Phase 3 trial.

Scotiabank downgraded Tempest Therapeutics (TPST) to Sector Perform from Outperform.Stay Ahead of the Market: Discover outperforming stocks ...

Tempest Therapeutics is exploring strategic alternatives for the business, including mergers, partnerships, acquisition, joint ventures and licensing agreements. Shares rose 9.2% to $7.81 in ...

Tempest Therapeutics (TPST) announced that the company plans to explore a full range of strategic alternatives to advance its clinical stage ...

Amezalpat (TPST-1120) is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular ...